Close Menu

NEW YORK – Personalis reported after the close of the market on Thursday that its first quarter revenues rose 36 percent year over year, driven by an increase in testing volume and analytical services provided to the US Department of Veterans Affairs Million Veteran Program (VA MVP).

For the three months ended March 31, the cancer genomics company reported revenues of $19.2 million, up from $14.1 million a year earlier, and beating the average Wall Street estimate of $17.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.